The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Open accessAbstract
Significance: Cancer immune evasion is well described. In some cases, this may be overcome by enhancing T-cell responses. We show that despite the presence of antitumor T cells, immunotherapeutic antibodies are ineffective in a murine pancreatic cancer model recapitulating the human disease. Removing the carcinoma-associated fibroblast (CAF) expressing fibroblast activation protein (FAP) from tumors permitted immune control of tumor growth and uncovered the efficacy of these immunotherapeutic antibodies. FAP + CAFs are the only tumoral source of chemokine (C-X-C motif) ligand 12 (CXCL12), and administering AMD3100, an inhibitor of chemokine (C-X-C motif) receptor 4, a CXCL12 receptor, also revealed the antitumor effects of an immunotherapeutic antibody and greatly diminished cancer cells. These findings may have wide clinical relevance because FAP + cells are found in almost all human adenocarcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeting CXCL12 signalling could be considered to be targeting CAFs as they are the major source of the chemokine in many tumours121.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“most studies have suggested an immunosuppressive role of CAFs121”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
In the citing paper
“the transcriptional profiles of apCAFs overlap with mesothelial cells150, and based on lineage tracing studies in mice have been postulated to derive from a mesothelial origin145”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [150]
In the citing paper
“They can further differentiate into myofibroblasts that express α-smooth muscle actin232.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [232]
In the citing paper
“fibroblast activation protein (FAP)+ CAFs inhibited anti-tumor function of T cells in gastric cancer and pancreatic cancer and targeting these FAP+ subtypes enhanced tumor response to ICB (Feig et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Feig et al., 2013
In the citing paper
“Moreover, CAF depletion using diphtheria toxin‐based immunotherapy reduced cancer growth by increasing CD8+ Teff‐cell infiltration to the TME [102].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Cited by
Sorted by citations
Items 501–600 of 1,000
Blair, A. B., Kim, V. M., Muth, S. T., Saung, M. T., Lokker, N. A., Blouw, B., Armstrong, T. D., Jaffee, E. M., Tsujikawa, T., Coussens, L. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4192 · Cited by 87
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny, B., Grossman, J. E., & Hidalgo, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3452 · Cited by 87
Bijlsma, M. F., & van Laarhoven, H. W. M. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9541-1 · Cited by 84
Zhang, B., Jiang, T., Shen, S., She, X., Tuo, Y., Hu, Y., Pang, Z., & Jiang, X. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.048 · Cited by 88
Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
Dougan, M. L., Ingram, J. R., Jeong, H., Mosaheb, M. M., Bruck, P. T., Ali, L. R., Pishesha, N., Blomberg, O. S., Tyler, P. M., Servos, M. M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0495 · Cited by 85
Liver Tropism in Cancer: The Hepatic Metastatic NichePreprint
Mielgo, A., & Schmid, M. C. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037259 · Cited by 86
The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment
Lafaro, K. J., & Melstrom, L. G. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.09.009 · Cited by 87
Liu, X., Xu, J., Zhang, B., Liu, J., Liang, C., Meng, Q., Hua, J., Yu, X., & Shi, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1117-9 · Cited by 87
Lifting the innate immune barriers to antitumor immunity
Rothlin, C. V., & Ghosh, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000695 · Cited by 83
Barilla, R., Diskin, B. E., Caso, R. C., Lee, K. B., Mohan, N., Buttar, C., Adam, S., Sekendiz, Z., Wang, J., Salas, R. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09416-2 · Cited by 81
Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors
Donnadieu, E., Dupré, L., Pinho, L. G., & Cotta-de-Almeida, V. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1mr0520-746r · Cited by 85
Modeling pancreatic cancer in mice for experimental therapeutics
Mallya, K. B., Gautam, S. K., Aithal, A., Batra, S. K., & Jain, M. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188554 · Cited by 88
Suarez‐Carmona, M., Williams, A., Schreiber, J., Hohmann, N., Prüfer, U., Krauß, J., Jäger, D., Frömming, A., Beyer, D., Eulberg, D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002505 · Cited by 82
Cancer‐Associated Fibroblasts Suppress Cancer Development: The Other Side of the Coin
Wang, Z., Yang, Q., Tan, Y., Tang, Y., Ye, J., Yuan, B., & Yu, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.613534 · Cited by 81
Yamamoto, K., Tateishi, K., Kudo, Y., Hoshikawa, M., Tanaka, M. H., Nakatsuka, T., Fujiwara, H., Miyabayashi, K., Takahashi, R., Tanaka, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11129 · Cited by 83
Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer
Zhao, J., Xiao, Z., Li, T., Chen, H., Yuan, Y., Wang, Y., Hsiao, C.-H., Chow, D. S., Overwijk, W. W., & Li, C. (2018) · ACS Nano · doi:10.1021/acsnano.8b02481 · Cited by 81
FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer
Canel, M., Sławińska, A., Lonergan, D. W., Kallor, A. A., Upstill‐Goddard, R., Davidson, C., von Kriegsheim, A., Biankin, A. V., Byron, A., Alfaro, J. A., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327927 · Cited by 81
Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer
Santagata, S., Napolitano, M., D’Alterio, C., Desicato, S., Maro, S. D., Marinelli, L., Fragale, A., Buoncervello, M., Persico, F., Gabriele, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20363 · Cited by 81
Maxwell, P. J., Neisen, J., Messenger, J., & Waugh, D. J. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2052 · Cited by 80
Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy
Liu, M., Song, W., & Huang, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.032 · Cited by 83
Targeting tumor innervation: premises, promises, and challenges
Li, X., Peng, X., Yang, S., Wei, S., Fan, Q., Liu, J., Yang, L., & Li, H. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00930-9 · Cited by 85
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 85
Engineering CAR-T Cells for Improved Function Against Solid Tumors
Morgan, M. A., & Schambach, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02493 · Cited by 80
The fibrotic and immune microenvironments as targetable drivers of metastasis
Boulter, L., Bullock, E., Mabruk, Z., & Brunton, V. G. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01172-1 · Cited by 78
Zheng, H., Liu, H., Li, H., Dou, W., & Wang, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.744677 · Cited by 77
Cancer‐associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets
Menezes, S., Okail, M. H., Jalil, S. M. A., Kocher, H. M., & Cameron, A. J. M. (2022) · The Journal of Pathology · doi:10.1002/path.5926 · Cited by 82
The Role of Cancer-Associated Fibroblasts in Ovarian Cancer
Zhang, M., Chen, Z., Wang, Y., Zhao, H., & Du, Y. (2022) · Cancers · doi:10.3390/cancers14112637 · Cited by 84
Achreja, A., Zhao, H., Yang, L., Yun, T. H., Marini, J. C., & Nagrath, D. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.01.001 · Cited by 81
Bobkov, V., Zarca, A. M., Hout, A. V., Arimont, M., Doijen, J., Bialkowska, M., Toffoli, E. C., Klarenbeek, A., van der Woning, B., van der Vliet, H. J., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.014 · Cited by 82
CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success
Long, K. B., Young, R. M., Boesteanu, A. C., Suhoski, M. M., Melenhorst, J. J., Lacey, S. F., Degaramo, D. A., Levine, B. L., & Fraietta, J. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02740 · Cited by 80
PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells
Inoue, C., Miki, Y., Saito, R., Hata, S., Abe, J., Sato, I., Okada, Y., & Sasano, H. (2019) · Cancers · doi:10.3390/cancers11091257 · Cited by 78
Advances in Pancreatic Ductal Adenocarcinoma Treatment
Anderson, E. M., Thomassian, S., Gong, J., Hendifar, A. E., & Osipov, A. (2021) · Cancers · doi:10.3390/cancers13215510 · Cited by 78
Li, H., Yang, Z., & Guo, Q. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00789-w · Cited by 86
Emerging Role of Cancer-Associated Fibroblasts-Derived Exosomes in Tumorigenesis
Peng, L., Wang, D., Han, Y., Huang, T., He, X., Wang, J., & Ou, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.795372 · Cited by 77
The peritumor microenvironment: physics and immunity
Zhang, S., Regan, K., Najera, J., Grinstaff, M. W., Datta, M., & Nia, H. T. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.04.004 · Cited by 76
Peng, Z., Tong, Z., Ren, Z., Ye, M., & Hu, K. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00665-y · Cited by 82
GPER is a mechanoregulator of pancreatic stellate cells and the tumor microenvironment
Cortés, E., Sarper, M., Robinson, B. K., Lachowski, D., Chronopoulos, A., Thorpe, S. D., Lee, D. A., & Hernández, A. E. D. R. (2018) · EMBO Reports · doi:10.15252/embr.201846556 · Cited by 81
Fibroblasts as Modulators of Local and Systemic Cancer Metabolism
Sanford-Crane, H., Abrego, J., & Sherman, M. H. (2019) · Cancers · doi:10.3390/cancers11050619 · Cited by 77
Nel, A. E., Mei, K., Liao, Y., & Liu, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c01252 · Cited by 81
Masugi, Y. (2022) · Cancers · doi:10.3390/cancers14133293 · Cited by 90
spaCI: deciphering spatial cellular communications through adaptive graph model
Tang, Z., Zhang, T., Yang, B., Su, J., & Song, Q. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac563 · Cited by 78
Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities
Caramelo, B., Zagorac, S., Corral, S., Marqués, M., & Real, F. X. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.02.011 · Cited by 81
The application of the fibroblast activation protein α-targeted immunotherapy strategy
Jiang, G., Xu, W., Du, J., Zhang, K.-S., Zhang, Q.-G., Wang, X.-W., Liu, Z.-G., Liu, S., Xie, W., Liu, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8098 · Cited by 80
Tulotta, C., Stefanescu, C., Chen, Q., Torraca, V., Meijer, A. H., & Snaar-Jagalska, E. B. (2019) · Scientific Reports · doi:10.1038/s41598-019-38643-2 · Cited by 77
Watanabe, S., Noma, K., Ohara, T., Kashima, H., Sato, H., Kato, T., Urano, S., Katsube, R., Hashimoto, Y., Tazawa, H., et al. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1617566 · Cited by 77
Liu, H., Shi, Y., & Qian, F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.012 · Cited by 78
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 84
Immune oncology, immune responsiveness and the theory of everything
Turan, T., Kannan, D., Patel, M. R., Barnes, J. M., Tanlimco, S. G., Lu, R. O., Halliwill, K. D., Kongpachith, S., Kline, D. E., Hendrickx, W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0355-5 · Cited by 76
Ionizing radiation effects on the tumor microenvironment
Portella, L., & Scala, S. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.07.003 · Cited by 78
Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma
Zhang, J., Gu, C., Song, Q., Zhu, M., Xu, Y., Xiao, M., & Zheng, W. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00488-y · Cited by 79
What is new in cancer-associated fibroblast biomarkers?
Zhao, Z., Li, T., Yuan, Y., & Zhu, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01125-0 · Cited by 79
Lee, E., Pandey, N. B., & Popel, A. S. (2015) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2015.2 · Cited by 75
Application of nanomaterials in cancer immunotherapy
Qian, H., Liu, B., & Jiang, X. (2018) · Materials Today Chemistry · doi:10.1016/j.mtchem.2018.01.001 · Cited by 75
TCR-engineered T cells to treat tumors: Seeing but not touching?
Debets, R., Donnadieu, E., Chouaı̈b, S., & Coukos, G. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.002 · Cited by 73
Liu, X., Jiang, J., Chang, C. H., Liao, Y., Lodico, J. J., Tang, I., Zheng, E., Qiu, W., Lin, M. J., Wang, X., et al. (2021) · Small · doi:10.1002/smll.202005993 · Cited by 73
Wang, Z., Moresco, P., Yan, R., Li, J., Gao, Y., Biasci, D., Yao, M., Pearson, J., Hechtman, J. F., Janowitz, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2119463119 · Cited by 74
Self-citationThe importance of being CAFs (in cancer resistance to targeted therapies)
Rizzolio, S., Giordano, S., & Corso, S. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02524-w · Cited by 75
Cheng, Y., Chen, X., Li, F., Yang, Z., Xiao, L., Xiang, B., Wang, X., Liu, D., Lin, P., Shi, J.-Y., et al. (2025) · Cell Discovery · doi:10.1038/s41421-024-00747-z · Cited by 80
Roy, I., McAllister, D. M., Gorse, E., Dixon, K. J., Piper, C., Zimmerman, N. P., Getschman, A. E., Tsai, S., Engle, D. D., Evans, D. B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2645 · Cited by 74
Solid Tumor Immunotherapy with T Cell Engager‐Armed Oncolytic Viruses
Scott, E. M., Duffy, M. R., Freedman, J. D., Fisher, K. D., & Seymour, L. W. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201700187 · Cited by 76
Progress in the Treatment of Metastatic Pancreatic Cancer and the Search for Next Opportunities
Ko, A. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7625 · Cited by 74
The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier
Pai, S. I., Cesano, A., & Marincola, F. M. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_6 · Cited by 74
Mills, B. N., Qiu, H., Drage, M. G., Chen, C., Mathew, J. S., Garrett-Larsen, J., Ye, J., Uccello, T. P., Murphy, J. D., Belt, B. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2495 · Cited by 75
Bu, M. T., Chandrasekhar, P., Ding, L., & Hugo, W. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108211 · Cited by 72
Chen, H., Guo, Q., Chu, Y., Li, C., Zhang, Y., Liu, P., Zhao, Z., Wang, Y., Luo, Y., Zhou, Z., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121599 · Cited by 75
Wong, P. F., Wei, W., Gupta, S., Smithy, J. W., Zelterman, D. A., Kluger, H. M., & Rimm, D. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0675-0 · Cited by 77
Nucleic Acid-Based Approaches for Tumor Therapy
Hager, S., Fittler, F. J., Wagner, E., & Bros, M. (2020) · Cells · doi:10.3390/cells9092061 · Cited by 78
Upadhrasta, S., & Zheng, L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091472 · Cited by 70
Yang, P., Hu, Y., & Zhou, Q. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191113113110 · Cited by 75
CXCL12 Signaling in the Tumor Microenvironment
Portella, L., Bello, A. M., & Scala, S. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-62658-7_5 · Cited by 72
Control of Dendritic Cell Function Within the Tumour Microenvironment
Hari‐Gupta, Y., Khanom, A., & Acton, S. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.733800 · Cited by 73
Boelaars, K., Rodríguez, E., Huinen, Z. R., Liu, C., Wang, D., Springer, B. O., Olesek, K., Kruijssen, L. J. W., van Ee, T., Lindijer, D., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06087-8 · Cited by 75
Self-citationFokas, E., O’Neill, E., Gordon-Weeks, A. N., Mukherjee, S., McKenna, W. G., & Muschel, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.12.001 · Cited by 75
The pancreatic cancer microenvironment: A true double agent
Melstrom, L. G., Salazar, M. D., & Diamond, D. J. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24643 · Cited by 74
Zhan, S., Liu, Z., Zhang, M., Guo, T., Quan, Q., Huang, L., Guo, L., Cao, L., & Zhang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01466 · Cited by 69
Cancer-associated fibroblasts, tumor and radiotherapy: interactions in the tumor micro-environment
Raaijmakers, K., Adema, G. J., Bussink, J., & Ansems, M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03251-0 · Cited by 78
Gorchs, L., Hellevik, T., Bruun, J., Camilio, K. A., Al‐Saad, S., Stuge, T. B., & Martínez-Zubiaurre, I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00087 · Cited by 71
The lymphatic system and pancreatic cancer
Fink, D. M., Steele, M. M., & Hollingsworth, M. A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.048 · Cited by 72
O’Malley, G., Heijltjes, M. T., Houston, A. M., Rani, S., Ritter, T., Egan, L. J., & Ryan, A. E. (2016) · Oncotarget · doi:10.18632/oncotarget.11354 · Cited by 72
Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors
Han, X., Xu, Y., Geranpayehvaghei, M., Anderson, G. J., Li, Y., & Nie, G. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119745 · Cited by 74
The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives
Wu, Y. F., Zhang, C., Jiang, K., Werner, J. M., Bazhin, A. V., & D’Haese, J. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.621937 · Cited by 74
Mechanisms of PDAC subtype heterogeneity and therapy response
Espinet, E., Klein, L., Puré, E., & Singh, S. K. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.08.005 · Cited by 70
Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy
Luo, Z., Eichinger, K. M., Zhang, A., & Li, S. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216396 · Cited by 71
Connecting the Metabolic and Immune Responses to Cancer
Flint, T. R., Fearon, D. T., & Janowitz, T. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.001 · Cited by 71
Self-citationOn the mechanism of long-range orientational order of fibroblasts
Li, X., Balagam, R., He, T.-F., Lee, P. P., Igoshin, O. A., & Levine, H. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707210114 · Cited by 70
Gunderson, A. J., Yamazaki, T., McCarty, K., Phillips, M., Alice, A. F., Bambina, S., Zebertavage, L., Friedman, D. J., Cottam, B., Newell, P., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211117 · Cited by 75
A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer
Bonneau, C., Eliès, A., Kieffer, Y., Bourachot, B., Ladoire, S., Pelon, F., Héquet, D., Guinebretière, J. M., Blanchet, C., Vincent‐Salomon, A., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01311-9 · Cited by 70
Érsek, B., Silló, P., Çakır, U., Molnár, V., Bencsik, A., Mayer, B., Mezey, É., Kárpáti, S., Pós, Z., & Németh, K. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03517-8 · Cited by 68
Gui, J., Zahedi, F., Ortiz, A., Cho, C., Katlinski, K. V., Alicea-Torres, K. M., Li, J., Todd, L., Zhang, H., Beiting, D. P., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0064-0 · Cited by 70
Feng, H., Liu, K., Shen, X., Liang, J., Wang, C., Qiu, W., Cheng, X., & Zhao, R. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03111-7 · Cited by 66
Kato, R., Haratani, K., Hayashi, H., Sakai, K., Sakai, H., Kawakami, H., Tanaka, K., Takeda, M., Yonesaka, K., Nishio, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01201-z · Cited by 71
Tenascin‐C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression
Murdamoothoo, D., Sun, Z., Yilmaz, A., Riegel, G., Fayçal, C. A., Deligne, C., Velázquez-Quesada, I., Erne, W., Nascimento, M., Mörgelin, M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013270 · Cited by 70
Imlimthan, S., Moon, E. S., Rathke, H. G., Afshar‐Oromieh, A., Rösch, F., Rominger, A., & Gourni, E. (2021) · Pharmaceuticals · doi:10.3390/ph14101023 · Cited by 76
Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma
Ray, A., Callaway, M. K., Rodríguez-Merced, N. J., Crampton, A. L., Carlson, M., Emme, K. B., Ensminger, E. A., Kinne, A. A., Schrope, J. H., Rasmussen, H. R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150330 · Cited by 66
Luo, W., Wen, T., & Qu, X. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02935-3 · Cited by 73
Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer
Shakiba, M., & Tuveson, D. A. (2025) · Nature Immunology · doi:10.1038/s41590-025-02134-6 · Cited by 81
Self-citationThree-dimensional bio-printing: A new frontier in oncology research
Charbe, N. B., McCarron, P. A., & Tambuwala, M. M. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i1.21 · Cited by 70
Fibroblast-Activating Protein: Targeting the Roots of the Tumor Microenvironment
Siveke, J. T. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.214361 · Cited by 69
The Tumor Microenvironment in Colorectal Cancer Therapy
Pedrosa, L., Esposito, F. M., Thomson, T. M., & Maurel, J. (2019) · Cancers · doi:10.3390/cancers11081172 · Cited by 73
Mezheyeuski, A., Segersten, U., Leiss, L. W., Malmström, P., Hatina, J., Östman, A., & Strell, C. (2020) · Scientific Reports · doi:10.1038/s41598-019-55013-0 · Cited by 68
Metadata
- Authors
- Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., Teichmann, S. A., Janowitz, T., Jodrell, D. I., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- MRC Laboratory of Molecular Biology (GB)
- Johns Hopkins University (US)
- Ludwig Collaborative Laboratory, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231; and
- European Bioinformatics Institute (GB)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-11-25
- Volume
- 110
- Issue
- 50
- Pages
- 20212-20217
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3864274
- OpenAlex
- W2086834665
- Cited by
- 2,100
- References
- 28
- Citations by year
- 2026: 252 · 2025: 157 · 2024: 226 · 2023: 214 · 2022: 221 · 2021: 244 · 2020: 203 · 2019: 149 · 2018: 125 · 2017: 119 · 2016: 95 · 2015: 63 · 2014: 30
- FWCI
- 33.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK (15678)
- National Institute for Health and Care Research (CL-2011-14-007)
- Medical Research Council (MC_PC_12012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- pancreatic ductal adenocarcinoma, CXCL12, fibroblast activation protein, cancer-associated fibroblasts, PD-L1 blockade, CTLA-4 blockade, tumor immune evasion, tumor stroma, CXCR4 inhibition, AMD3100, CD8+ T cells, chemokine signaling, immunotherapy resistance
- MeSH terms
- Cyclams, Fibroblast Activation Protein Alpha, Analysis of Variance, Animals, Base Sequence, Benzylamines, Fibroblasts, Flow Cytometry, Fluorescent Antibody Technique, Heterocyclic Compounds, Immunohistochemistry, Immunotherapy, Membrane Proteins, Molecular Sequence Data, Pancreatic Neoplasms, Endopeptidases, Serine Endopeptidases, Sequence Analysis, RNA, Gelatinases, Tumor Escape, Carcinoma, Pancreatic Ductal, Mice, Chemokine CXCL12, Enzyme-Linked Immunospot Assay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
